PrPres and TSE Strains

Strains of TSE agent have been described for CJD (90), scrapie (68,69), and hamster-adapted TME (7). Strains in the TSE are defined by differences in brain pathology, disease incubation time, clinical disease, species tropism, and PrP-res properties (for review, see ref. 19). It is especially challenging to explain TSE strains in terms of PrP-res formation since multiple strains have been described in species with one PrP genotype. It is difficult to imagine how PrP-res with the same amino acid sequence could cause several different disease phenotypes. Since the TSE diseases appear to be diseases of protein folding, however, the answer may reside not in the amino acid sequence but rather in the conformation of the protein. This hypothesis is supported by data from studies using protease digestion of hamster-adapted TME strains (6). If PrP-res can adopt several stable variations in structure, it might be able to pass on its own strain-specific characteristics to PrP-sen via direct PrP-PrP interactions. In fact, recent structural data using infrared spectroscopy (29) or a conformation-dependent immunoassay (118) show that PrP-res from different mouse and hamster TSE strains have different conformations.

3.3.1. PrP-res Conformation and Strains

Two strains of hamster scrapie originally derived from mink infected with TME (7) have provided the best studied example of strain-specific differences in PrP-res conformation. In both strains, PrP-res is derived from the same hamster PrP-sen, but PrP-res derived from hamster brains infected with the "drowsy" strain is approx 1 kDa smaller than PrP-res derived from hamster brains infected with the "hyper" strain (7). When drowsy or hyper PrP-res were mixed with the same radiolabeled PrP-sen precursor in the cell-free conversion system (Fig. 5A), the strain-specific size difference could be detected in the newly made protease-resistant PrP. Thus, protease-resistant PrP generated by drowsy-derived PrP-res was approx 1 kDa smaller than that generated from hyper PrP-res (5,8). In vivo studies using transgenic mice infected with different strains of human CJD also imply that TSE strains may be dependent on the conformation of PrP-res (36,131). Thus, there is evidence to support the hypothesis that self-propagation of PrP-res may proceed via distinctive three-dimensional structures, which in turn could provide some molecular basis for scrapie strains.

3.3.2. PrP-res Glycosylation and Strains

It has also been suggested that PrP-res glycosylation, which can differ between strains (Fig. 5B), might also encode strain-specific phenotypes. However, in vivo studies have suggested that PrP glycosylation does not encode strain characteristics. Strain-specific characteristics are maintained upon transmission of infectivity from one animal to another even when the infected tissues contain PrP-res molecules with very different glycosylation patterns (54,115). The most recent evidence suggests that strain-specific PrP-res glycosylation does not encode strain-specific phenotypes but rather may be indicative of the cellular compartment where the majority of strain-specific PrP-res formation occurs (137).

3.4. PrP-res and Familial TSE

Although there is no correlation with exposure to an infectious agent, TSE agent infectivity is detectable in the brains of individuals afflicted with familial TSE. Intrigu-ingly, PrP-res is also detectable in most familial forms of human TSE, although its size may vary. The question then is how exactly abnormal PrP is generated in familial TSE in the absence of exposure to PrP-res from an exogenous source. Since these diseases are heritable, genetics must play a role. Given the critical role that PrP has in infectious forms of TSE, the most likely genetic component is the PrP gene itself. In fact, familial TSE diseases have been correlated with particular mutations in the PrP gene (Fig. 7) and in most families association of the PrP genotype with onset of disease (i.e. penetrance) is 100%. As seen in Fig. 7, these mutations occur throughout most of the PrP molecule, although many are clustered toward the C-terminus. The current hypothesis is that mutations in the PrP gene lead to a PrP molecule that is more likely to convert spontaneously to the abnormal form. The difference between this type of "spontaneous" conversion and the "induced" conversion associated with exposure to infectivity is that both PrP-sen and PrP-res are derived from the host.

It is now quite clear that mutant PrP molecules have properties different from wildtype PrP and that these altered properties lead to a molecule with properties reminiscent of PrP-res. Insertion of extra copies of an octapeptide repeat in PrP (Fig. 7) has been associated with CJD in several different families and is probably the best studied familial TSE mutant. These mutants are processed differently (39,76) and somewhat resemble PrP-res in that as the number of octapeptide repeats increases they have a greater tendency to aggregate as well as an increased resistance to proteinase K (77,98). Transgenic mice overexpressing one of these mutants even develop a neurological disease (34). Other PrP familial mutations demonstrate different phenotypes. PrP with the Gerstmann-Straussler-Scheinker (GSS)-associated aspartic acid to asparagine mutation at codon 178 shows an altered cell surface expression (92). Mice overexpressing the GSS-associated proline to leucine mutation at codon 102 develop a neurodegenerative disease (62), although transgenic mice expressing wild-type levels of this mutant PrP protein do not (81). Thus, these data suggest that overexpression of the mutant protein may be required for disease. Altered PrP processing has also been linked to a PrP mutation linked to GSS. Mutation of an alanine to a valine at codon 117 results in an increase in transmembrane forms of PrP (79), and transgenic mice overexpressing this PrP mutant develop a neurological disease and are more susceptible to scrapie infection (53).

Although all these studies show that mutant PrP molecules behave differently in vitro and in vivo, the nature of their role in pathogenesis remains unclear. Although most of these PrP mutants are slightly more resistant to proteinase K, their level of resistance is several hundred fold less than that of PrP-res isolated from the brain. In fact, when tested in the cell-free conversion system, PrP mutants containing extra copies of the octapeptide repeat region were unable to form PrP-res spontaneously and were no different from nonmutant PrP in their ability to induce PrP-res formation (98). Thus, despite all these recent advances, the molecular basis for familial TSE remains an open question and may in fact differ for different familial TSEs.

Fig. 7. Mutations in human PrP associated with familial TSE. The structure of human PrP is shown (143). The positions of the signal peptide cleavage at the N-terminus and the GPI anchor addition site at the C-terminus are indicated by the scissors. The open boxes labeled "Repeats" represent an octapeptide sequence that is tandemly repeated five times in normal human PrP. The triple-headed arrows represent the two N-linked glycosylation sites. The asterisks indicate the site of proteinase K cleavage, which can vary somewhat in PrP-res isolated from familial TSE cases. The locations of single amino acid mutations and insertion or deletion mutants associated with familial TSE are indicated (see ref. 48 for review).

Fig. 7. Mutations in human PrP associated with familial TSE. The structure of human PrP is shown (143). The positions of the signal peptide cleavage at the N-terminus and the GPI anchor addition site at the C-terminus are indicated by the scissors. The open boxes labeled "Repeats" represent an octapeptide sequence that is tandemly repeated five times in normal human PrP. The triple-headed arrows represent the two N-linked glycosylation sites. The asterisks indicate the site of proteinase K cleavage, which can vary somewhat in PrP-res isolated from familial TSE cases. The locations of single amino acid mutations and insertion or deletion mutants associated with familial TSE are indicated (see ref. 48 for review).

4. Conclusions

In the study of TSE diseases at both the molecular and pathogenic level, a great many questions remain. For example, how could different conformations of PrP-res lead to different lesion profiles in the brain? Are other molecules involved in PrP-res formation and how could these potential cofactors influence disease? How does the infectious agent enter a cell? For that matter, the question of whether or not PrP-res is actually the infectious agent remains unresolved largely because, owing to the difficulty in purifying or generating new PrP-res, it has never been shown that PrP-res alone can induce disease.

Independent of our understanding the mechanisms of TSE disease, and within the context of the current situation in Great Britain and elsewhere, the most important areas of TSE research are early diagnosis of the disease and development of anti-TSE prophylactic and therapeutic agents. It is still impossible to diagnose CJD in humans prior to the onset of clinical signs, and thus the disease is always fatal. New tests to detect a protein (14-3-3) that is associated with neurological damage (38), the potential for using tonsil biopsy or urinalysis to detect PrP-res prior to the onset of clinical signs (54,125), and a technique to amplify PrP-res (116) are all promising. Identifying effective inhibitors of TSE disease is also of the highest priority. Many different compounds have already been shown to inhibit PrP-res formation and/or delay disease (see ref. 18 for review). Although most of these compounds can delay disease onset, none can actually prevent disease if given just a few days after infection nor can any be used after the onset of clinical signs. The search for rapid diagnostic tests and effective anti-TSE drugs is ongoing and critically important if the threat of TSE as a re-emerging disease is to be overcome.


1 Alper, T., Cramp, W. A., Haig, D. A., and Clarke, M. C. (1967) Does the agent of scrapie replicate without nucleic acid? Nature 214, 764-766.

2. Anderson, R. M., Donnelly, C. A., Ferguson, N. M., et al. (1996) Transmission dynamics and epidemiology of BSE in British cattle. Nature 382, 779-788.

3. Barron, R. M., Thomson, V., Jamieson, E., et al. (2001) Changing a single amino acid in the N-terminus of murine PrP alters TSE incubation time across three species barriers. EMBO J. 20, 5070-5078.

4. Beranger, F., Mange, A., Goud, B., and Lehmann, S. (2002) Stimulation of PrP(C) retrograde transport toward the endoplasmic reticulum increases accumulation of PrP(Sc) in prion-infected cells. J. Biol. Chem. 277, 38,972-38,977.

5. Bessen, R. A., Kocisko, D. A., Raymond, G. J., Nandan, S., Lansbury, P. T. Jr., and Caughey, B. (1995) Nongenetic propagation of strain-specific phenotypes of scrapie prion protein. Nature 375, 698-700.

6. Bessen, R. A. and Marsh, R. F. (1992) Biochemical and physical properties of the prion protein from two strains of transmissible mink encephalopathy agent. J. Virol. 66, 2096-2101.

7. Bessen, R. A. and Marsh, R. F. (1994) Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy. J. Virol. 68, 7859-7868.

8. Bessen, R. A., Raymond, G. J., and Caughey, B. (1997) In situ formation of protease-resistant prion protein in transmissible spongiform encephalopathy-infected brain slices. J. Biol. Chem. 272, 15,227-15,231.

9. Bolton, D. C. and Bendheim, P. E. (1988). A modified host protein model of scrapie. In: Novel Infectious Agents and the Central Nervous System (Bock, G. and Marsh, J., eds.). John Wiley & Sons, Chichester, pp. 164-181.

10. Bolton, D. C., Bendheim, P. E., Marmostein, A. D., and Potempska, A. (1987). Isolation and structural studies of the intact scrapie agent protein. Arch. Biochem. Biophys. 258, 579-590.

11. Bolton, D. C., McKinley, M. P., and Prusiner, S. B. (1982). Identification of a protein that purifies with the scrapie prion. Science 218, 1309-1311.

12. Borchelt, D. R., Scott, M., Taraboulos, A., Stahl, N., and Prusiner, S. B. (1990). Scrapie and cellular prion proteins differ in the kinetics of synthesis and topology in cultured cells. J. Cell Biol. 110, 743-752.

13. Borchelt, D. R., Taraboulos, A., and Prusiner, S. B. (1992). Evidence for synthesis of scrapie prion protein in the endocytic pathway. J. Biol. Chem. 267, 16188-16199.

14. Bossers, A., Belt, P. B. G. M., Raymond, G. J., Caughey, B., de Vries, R., and Smits, M. A. (1997). Scrapie susceptibility-linked polymorphisms modulate the in vitro conversion of sheep prion protein to protease-resistant forms. Proc. Natl. Acad. Sci. USA 94, 4931-4936.

15. Bounhar, Y., Zhang, Y., Goodyer, C. G., and LeBlanc, A. (2001). Prion protein protects human neurons against Bax-mediated apoptosis. J. Biol. Chem. 276, 39145-39149.

16. Bradley, R. and Wilesmith, J. W. (1993). Epidemiology and control of bovine spongiform encephalopathy (BSE). Br. Med. Bull. 49, 932-959.

17. Brandner, S., Isenmann, S., Raeber, A., et al. (1996) Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 379, 339-343.

18. Brown, P. (2002) Drug therapy in human and experimental transmissible spongiform encephalopathy. Neurology 58, 1720-1725.

19. Bruce, M. E. (1996) Strain typing studies of scrapie and BSE. In: Methods in Molecular Medicine: Prion Diseases (Baker, H. and Ridley, R. M., eds.). Humana Press, Totowa, NJ, pp. 223-236.

20. Bruce, M. E., Will, R. G., Ironside, J. W., et al. (1997) Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 389, 498-501.

21. Bueler, H., Aguzzi, A., Sailer, A., et al. (1993) Mice devoid of PrP are resistant to scrapie. Cell 73, 1339-1347.

22. Butler, D. A., Scott, M. R. D., Bockman, J. M., et al. (1988) Scrapie-infected murine neuroblastoma cells produce protease-resistant prion proteins. J. Virol. 62, 1558-1564.

23. Cashman, N. R., Loertscher, R., Nalbantoglu, J., et al. (1990) Cellular isoform of the scrapie agent protein participates in lymphocyte activation. Cell 61, 185-192.

24. Caughey, B., Brown, K., Raymond, G. J., Katzenstien, G. E., and Thresher, W. (1994) Binding of the protease-sensitive form of PrP (prion protein) to sulfated glycosaminogly-can and Congo red. J. Virol. 68, 2135-2141.

25. Caughey, B., Neary, K., Buller, R., et al. (1990) Normal and scrapie-associated forms of prion protein differ in their sensitivities to phospholipase and proteases in intact neuroblastoma cells. J. Virol. 64, 1093-1101.

26. Caughey, B., Race, R. E., Ernst, D., Buchmeier, M. J., and Chesebro, B. (1989) Prion protein (PrP) biosynthesis in scrapie-infected and uninfected neuroblastoma cells. J. Virol. 63, 175-181.

27. Caughey, B. and Raymond, G. J. (1991) The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. J. Biol. Chem. 266, 18,217-18,223.

28. Caughey, B. and Raymond, G. J. (1993) Sulfated polyanion inhibition of scrapie-associ-ated PrP accumulation in cultured cells. J. Virol. 67, 643-650.

29. Caughey, B., Raymond, G. J., and Bessen, R. A. (1998) Strain-dependent differences in beta-sheet conformations of abnormal prion protein. J. Biol. Chem. 273, 32,230-32,235.

30. Caughey, B., Raymond, G. J., Ernst, D., and Race, R. E. (1991) N-terminal truncation of the scrapie-associated form of PrP by lysosomal protease(s): implications regarding the site of conversion of PrP to the protease-resistant state. J. Virol. 65, 6597-6603.

31. Caughey, B., Raymond, G. J., Kocisko, D. A., and Lansbury, P. T., Jr. (1997) Scrapie infectivity correlates with converting activity, protease resistance, and aggregation of scrapie-associated prion protein in guanidine denaturation studies. J. Virol. 71,4107-4110.

32. Caughey, B. W., Dong, A., Bhat, K. S., Ernst, D., Hayes, S. F., and Caughey, W. S. (1991) Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy. Biochemistry 30, 7672-7680.

33. Chabry, J., Caughey, B., and Chesebro, B. (1998) Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides. J. Biol. Chem. 273, 13,203-13,207.

34. Chiesa, R., Piccardo, P., Ghetti, B., and Harris, D. A. (1998) Neurological illness in transgenic mice expressing a prion protein with an insertional mutation. Neuron 21, 1339-1351.

35. Collinge, J., Palmer, M. S., Sidle, K. C., et al. (1995) Unaltered susceptibility to BSE in transgenic mice expressing human prion protein. Nature 378, 779-783.

36. Collinge, J., Sidle, K. C. L., Meads, J., Ironside, J., and Hill, A. F. (1996) Molecular analysis of prion strain variation and the aetiology of "new variant" CJD. Nature 383, 685-690.

37. Collinge, J., Whittington, M. A., Sidle, K. C., et al. (1994) Prion protein is necessary for normal synaptic function. Nature 370, 295-297.

38. Collins, S., Boyd, A., Fletcher, A., et al. (2000) Creutzfeldt-Jakob disease: diagnostic utility of 14-3-3 protein immunodetection in cerebrospinal fluid. J. Clin. Neurosci. 7, 203-208.

39. Daude, N., Lehmann, S., and Harris, D. A. (1997) Identification of intermediate steps in the conversion of a mutant prion protein to a scrapie-like form in cultured cells. J. Biol. Chem. 272, 11,604-11,612.

40. DebBurman, S. K., Raymond, G. J., Caughey, B., and Lindquist, S. (1997) Chaperone-supervised conversion of prion protein to its protease-resistant form. Proc. Natl. Acad. Sci. USA 94, 13,938-13,943.

41. Diringer, H., Gelderblom, H., Hilmert, H., Ozel, M., Edelbluth, C., and Kimberlin, R. H. (1983) Scrapie infectivity, fibrils and low molecular weight protein. Nature 306,476-478.

42. Donne, D. G., Viles, J. H., Groth, D., et al. (1997) Structure of the recombinant full-length hamster prion protein PrP(29-231): the N terminus is highly flexible. Proc. Natl. Acad. Sci. USA 94, 13,452-13,457.

43. Fischer, M., Rulicke, T., Raeber, A., et al. (1996) Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J. 15,1255-1264.

44. Gabizon, R., Meiner, Z., Halimi, M., and Bensasson, S. A. (1993) Heparin-like molecules bind differentially to prion proteins and change their intracellular metabolic-fate. J. Cell. Physiol. 157, 319-325.

45. Gadjusek, D. C. (1988) Transmissible and nontransmissible amyloidoses: autocatalytic post-translational conversion of host precursor proteins to beta-pleated configurations. J. Neuroimmunol. 20, 95-110.

46. Gasset, M., Baldwin, M. A., Fletterick, R. J., and Prusiner, S. B. (1993) Perturbation of the secondary structure of the scrapie prion protein under conditions that alter infectivity. Proc. Natl. Acad. Sci. USA 90, 1-5.

47. Glover, J. R., Kowal, A. S., Schirmer, E. C., Patino, M. M., Liu, J., and Lindquist, S. (1997) Self-seeded fibers formed by sup35, the protein determinant of [PSI+], a heritable prion-like factor of S. cerevisiae. Cell 89, 811-819.

48. Goldfarb, L. G., Cervenakova, L., Brown, P., and Gajdusek, D. C. (1996) Genotype-phe-notype correlations in familial spongiform encephalopathies associated with insert mutations. In: Transmissible Subacute Spongiform Encephalopathies: Prion Diseases (Court, L. and Dodet, B., eds.). Elsevier, Paris, pp. 425-431.

49. Goldmann, W., Hunter, N., Smith, G., Foster, J., and Hope, J. (1994) PrP genotype and agent effects in scrapie: change in allelic interaction with different isolates of agent in sheep, a natural host of scrapie. J. Gen. Virol. 75, 989-995.

50. Goldmann, W., Martin, T., Foster, J., ett al. (1996) Novel polymorphisms in the caprine PrP gene: a codon 142 mutation associated with scrapie incubation period. J. Gen. Virol. 77, 2885-2891.

51. Griffith, J. S. (1967) Self-replication and scrapie. Nature 215, 1043-1044.

52. Haraguchi, T., Fisher, S., Olofsson, S., et al. (1989) Asparagine-linked glycosylation of the scrapie and cellular prion proteins. Arch. Biochem. Biophys. 274, 1-13.

53. Hegde, R. S., Mastrianni, J. A., Scott, M. R., et al. (1998) A transmembrane form of the prion protein in neurodegenerative disease. Science 279, 827-834.

54. Hill, A. F., Butterworth, R. J., Joiner, S., et al. (1999) Investigation of variant CreutzfeldtJakob disease and other human prion diseases with tonsil biopsy samples. Lancet 353, 183-189.

55. Hill, A. F., Joiner, S., Linehan, J., Desbruslais, M., Lantos, P. L., and Collinge, J. (2000) Species-barrier-independent prion replication in apparently resistant species. Proc. Natl. Acad. Sci. USA 97, 10248-10253.

56. Holscher, C., Delius, J., and Burkle, A. (1998) Overexpression of nonconvertible PrPC del114-121 in scrapie-infected mouse neuroblastoma cells leads to trans-dominant inhibition of wild-type PrPSc accumulation. J. Virol. 72, 1153-1159.

57. Hope, J., Morton, L. J. D., Farquhar, C. F., Multhaup, G., Beyreuther, K., and Kimberlin, R. H. (1986) The major polypeptide of scrapie-associated fibrils (SAF) has the same size, charge distribution and N-terminal protein sequence as predicted for the normal brain protein (PrP). EMBO J. 5, 2591-2597.

58. Hope, J., Multhaup, G., Reekie, L. J. D., Kimberlin, R. H., and Beyreuther, K. (1988) Molecular pathology of scrapie-associated fibril protein (PrP) in mouse brain affected by the ME7 strain of scrapie. Eur. J. Biochem. 172, 271-277.

59. Horiuchi, M., Baron, G. S., Xiong, L. W., and Caughey, B. (2001) Inhibition of interactions and interconversions of prion protein isoforms by peptide fragments from the C-terminal folded domain. J. Biol. Chem. 276, 15,489-15,497.

60. Horiuchi, M., Chabry, J., and Caughey, B. (1999) Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. EMBO J. 18, 3193-3203.

61. Horiuchi, M., Priola, S. A., Chabry, J., and Caughey, B. (2000) Interactions between heterologous forms of prion protein: binding, inhibition of conversion, and species barriers. Proc. Natl. Acad. Sci. USA 97, 5836-5841.

62. Hsiao, K. K., Scott, M., Foster, D., Groth, D. F., DeArmond, S. J., and Prusiner, S. B. (1990) Spontaneous neurodegeneration in transgenic mice with mutant prion protein. Science 250, 1587-1590.

63. Jarrett, J. T. and Lansbury, P. T., Jr. (1993) Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73,1055-1058.

64. Jeffrey, M., Goodsir, C. M., Bruce, M., McBride, P. A., Scott, J. R., and Halliday, W. G. (1994) Correlative light and electron microscopy studies of PrP localisation in 87V scrapie. Brain Res. 656, 329-343.

65. Jeffrey, M., Goodsir, C. M., Bruce, M. E., McBride, P. A., Fowler, N., and Scott, J. R. (1994) Murine scrapie-infected neurons in vivo release excess prion protein into the extracellular space. Neurosci. Lett. 174, 39-42.

66. Jeffrey, M., Goodsir, C. M., Holliman, A., ett al. (1998) Determination of the frequency and distribution of vascular and parenchymal amyloid with polyclonal and N-terminal-specific PrP antibodies in scrapie-affected sheep and mice. Vet. Rec. 142, 534-537.

67. Jeffrey, M., Martin, S., Barr, J., Chong, A., and Fraser, J. R. (2001) Onset of accumulation of PrPRES in murine ME7 scrapie in relation to pathological and PrP immunohistochemi-cal changes. J. Comp. Path. 124, 20-28.

68. Kascsak, R. J., Rubenstein, R., Merz, P. A., et al. (1986) Immunological comparison of scrapie-associated fibrils isolated from animals infected with four different scrapie strains. J. Virol. 59, 676-683.

69. Kascsak, R. J., Rubenstein, R., Merz, P. A., Carp, R. I., Wisniewski, H. M., and Diringer, H. (1985) Biochemical differences among scrapie-associated fibrils support the biological diversity of scrapie agents. J. Gen. Virol. 66, 1715-1722.

70. Kimberlin, R. H. and Walker, C. A. (1986) Suppression of scrapie infection in mice by heteropolyanion 23, dextran sulfate, and some other polyanions. Antimicrob. Agents Chemother. 30, 409-413.

71. Knaus, K. J., Morillas, M., Swietnicki, W., Malone, M., Surewicz, W. K., and Yee, V. C. (2001) Crystal structure of the human prion protein reveals a mechanism for oligomeriza-tion. Nat. Struct. Biol. 8, 770-774.

72. Kocisko, D. A., Come, J. H., Priola, S. A., et al. (1994) Cell-free formation of protease-resistant prion protein. Nature 370, 471-474.

73. Kocisko, D. A., Lansbury, P. T., Jr., and Caughey, B. (1996) Partial unfolding and refolding of scrapie-associated prion protein: evidence for a critical 16-kDa C-terminal domain. Biochemistry 35, 13,434-13,442.

74. Kocisko, D. A., Priola, S. A., Raymond, G. J., Chesebro, B., Lansbury, P. T., Jr., and Caughey, B. (1995) Species specificity in the cell-free conversion of prion protein to pro-tease-resistant forms: a model for the scrapie species barrier. Proc. Natl. Acad. Sci. USA 92, 3923-3927.

75. Lawson, V. A., Priola, S. A., Wehrly, K., and Chesebro, B. (2001) N-terminal truncation of prion protein affects both formation and conformation of abnormal protease-resistant prion protein generated in vitro. J. Biol. Chem. 276, 35,265-35,271.

76. Lehmann, S. and Harris, D. A. (1995) A mutant prion protein displays an aberrant membrane association when expressed in cultured cells. J. Biol. Chem. 270, 24,589-24,597.

77. Lehmann, S. and Harris, D. A. (1996) Mutant and infectious prion proteins display common biochemical properties in cultured cells. J. Biol. Chem. 271, 1633-1637.

78. Locht, C., Chesebro, B., Race, R., and Keith, J. M. (1986) Molecular cloning and complete sequence of prion protein cDNA from mouse brain infected with the scrapie agent. Proc. Natl. Acad. Sci. USA 83, 6372-6376.

79. Lopez, C. D., Yost, C. S., Prusiner, S. B., Myers, R. M., and Lingappa, V. R. (1990) Unusual topogenic sequence directs prion protein biogenesis. Science 248, 226-229.

80. Manson, J. C., Clarke, A. R., McBride, P. A., McConnell, I., and Hope, J. (1994) PrP gene dosage determines the timing but not the final intensity or distribution of lesions in scrapie pathology. Neurodegeneration 3, 331-340.

81. Manson, J. C., Jamieson, E., Baybutt, H., et al. (1999) A single amino acid alteration (101L) introduced into murine PrP dramatically alters incubation time of transmissible spongiform encephalopathy. EMBO J. 18,6855-6864.

82. Marsh, R. F. and Kimberlin, R. H. (1975) Comparison of scrapie and transmissible mink encephalopathy in hamsters. II. Clinical signs, pathology, and pathogenesis. J. Infect. Dis. 131, 104-110.

83. McKinley, M. P., Taraboulos, A., Kenaga, L., et al. (1991) Ultrastructural localization of scrapie prion proteins in cytoplasmic vesicles of infected cultured cells. Lab. Invest. 65, 622-630.

84. Merz, P. A., Somerville, R. A., Wisniewski, H. M., and Iqbal, K. (1981) Abnormal fibrils from scrapie-infected brain. Acta Neuropathol. 54, 63-74.

85. Merz, P. A., Somerville, R. A., Wisniewski, H. M., Manuelidis, L., and Manuelidis, E. E. (1983) Scrapie associated fibrils in Creutzfeldt-Jakob disease. Nature 306, 474-476.

86. Mouillet-Richard, S., Ermonval, M., Chebassier, C., et al. (2000) Signal transduction through prion protein. Science 289, 1925-1928.

87. Paitel, E., Fahraeus, R., and Checler, F. (2003) Cellular prion protein sensitizes neurons to apoptotic stimuli through Mdm2-regulated and p53-dependent caspase 3-like activation. J. Biol. Chem. 278, 10,061-10,066.

88. Palmer, M. S., Dryden, A. J., Hughes, J. T., and Collinge, J. (1991) Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature 352, 340-342.

89. Pan, K.-M., Baldwin, M., Nguyen, J., et al. (1993) Conversion of alpha-helices into betasheets features in the formation of the scrapie prion protein. Proc. Natl. Acad. Sci. USA 90, 10,962-10,966.

Parchi, P., Castellani, R., Capellari, S., et al. (1996) Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann. Neurol. 39, 767-778. Paushkin, S. V., Kushnirov, V. V., Smirnov, V. N., and Ter-Avanesyan, M. D. (1997) In vitro propagation of the prion-like state of yeast Sup35 protein. Science 277, 381-383. Petersen, R. B., Parchi, P., Richardson, S. L., Urig, C. B., and Gambetti, P. (1996) Effect of the D178N mutation and the codon 129 polymorphism on the metabolism of the prion protein. J. Biol. Chem. 271, 12,661-12,668.

Priola, S. A. (1999) Prion protein and species barriers in the transmissible spongiform encephalopathies. Biomed. Pharmacother. 53, 27-33.

Priola, S. A. and Caughey, B. (1994) Inhibition of scrapie-associated PrP accumulation: Probing the role of glycosaminoglycans in amyloidogenesis. Mol. Neurobiol. 8, 113-120. Priola, S. A., Caughey, B., Race, R. E., and Chesebro, B. (1994) Heterologous PrP molecules interfere with accumulation of protease-resistant PrP in scrapie-infected murine neuroblastoma cells. J. Virol. 68, 4873-4878.

Priola, S. A., Chabry, J., and Chan, K. (2001) Efficient conversion of normal prion protein (PrP) by abnormal hamster PrP is determined by homology at amino acid residue 155. J. Virol. 75, 4673-4680.

Priola, S. A. and Chesebro, B. (1995) A single hamster amino acid blocks conversion to protease-resistant PrP in scrapie-infected mouse neuroblastoma cells. J. Virol. 69, 7754-7758.

Priola, S. A. and Chesebro, B. (1998) Abnormal properties of prion protein with inser-tional mutations in different cell types. J. Biol. Chem. 273, 11,980-11,985. Priola, S. A. and Lawson, V. A. (2001) Glycosylation influences cross-species formation of protease-resistant prion protein. EMBO J. 20, 6692-6699.

Prusiner, S. B. (1982) Novel proteinaceous infectious particles cause scrapie. Science 216, 136-144.

Prusiner, S. B. (1991) Molecular biology of prion diseases. Science 252, 1515-1522. Prusiner, S. B., Scott, M., Foster, D., et al. (1990) Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication. Cell 63, 673-686. Race, R. and Chesebro, B. (1998) Scrapie infectivity found in resistant species. Nature 392, 770.

Race, R., Meade-White, K., Raines, A., Raymond, G. J., Caughey, B., and Chesebro, B. (2002) Subclinical scrapie infection in a resistant species: persistence, replication, and adaptation of infectivity during four passages. J. Infect. Dis. 186(suppl 2), S166-S170. Race, R., Raines, A., Raymond, G. J., Caughey, B., and Chesebro, B. (2001) Long-term subclinical carrier state precedes scrapie replication and adaptation in a resistant species: analogies to bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease in humans. J. Virol. 75, 10,106-10,112.

Race, R. E., Caughey, B., Graham, K., Ernst, D., and Chesebro, B. (1988) Analyses of frequency of infection, specific infectivity, and prion protein biosynthesis in scrapie-infected neuroblastoma cell clones. J. Virol. 62, 2845-2849.

Race, R. E., Fadness, L. H., and Chesebro, B. (1987) Characterization of scrapie infection in mouse neuroblastoma cells. J. Gen. Virol. 68, 1391-1399. Race, R. E., Priola, S. A., Bessen, R. A., et al. (1995) Neuron-specific expression of a hamster prion protein minigene in transgenic mice induces susceptibility to hamster scrapie agent. Neuron 15, 1183-1191.

109. Raeber, A. J., Race, R. E., Brandner, S., et al. (1997) Astrocyte-specific expression of hamster prion protein (PrP) renders PrP knockout mice susceptible to hamster scrapie. EMBO J. 16, 6057-6065.

110. Raymond, G. J., Bossers, A., Raymond, L. D., et al. (2000) Evidence of a molecular barrier limiting susceptibility of humans, cattle and sheep to chronic wasting disease. EMBO J. 19, 4425-4430.

111. Raymond, G. J., Hope, J., Kocisko, D. A., et al. (1997) Molecular assessment of the transmissibilities of BSE and scrapie to humans. Nature 388, 285-288.

112. Riek, R., Hornemann, S., Wider, G., Billeter, M., Glockshuber, R., and Wuthrich, K. (1996) NMR structure of the mouse prion protein domain PrP(121-231) Nature 382, 180-182.

113. Riek, R., Hornemann, S., Wider, G., Glockshuber, R., and Wuthrich, K. (1997) NMR characterization of the full-length recombinant murine prion protein, mPrP(23-21). FEBS Lett. 413, 282-288.

114. Rubenstein, R., Carp, R. I., and Callahan, S. M. (1984) In vitro replication of scrapie agent in a neuronal model: infection of PC12 cells. J. Gen. Virol. 65, 2191-2198.

115. Rubenstein, R., Merz, P. A., Kascsak, R. J., et al. (1991) Scrapie-infected spleens: analysis of infectivity, scrapie-associated fibrils, and protease-resistant proteins. J. Infect. Dis. 164, 29-35.

116. Saborio, G. P., Permanne, B., and Soto, C. (2001) Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 411, 810-813.

117. Safar, J., Roller, P. P., Gajdusek, D. C., and Gibbs, C. J. Jr. (1993) Thermal stability and conformational transitions of scrapie amyloid (prion) protein correlate with infectivity. Protein Sci. 2, 2206-2216.

118. Safar, J., Wille, H., Itri, V., et al. (1998) Eight prion strains have PrP(Sc) molecules with different conformations [see comments]. Nat. Med. 4, 1157-1165.

119. Sakaguchi, S., Katamine, S., Nishida, N., et al. (1996) Loss of cerebellar Purkinje cells in aged mice homozygous for a disrupted PrP gene. Nature 380, 528-531.

120. Schatzl, H. M., Laszlo, L., Holtzman, D. M., et al. (1997) A hypothalamic neuronal cell line persistently infected with scrapie prions exhibits apoptosis. J. Virol. 71,8821-8831.

121. Scott, M., Foster, D., Mirenda, C., et al. (1989) Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques. Cell 59, 847-857.

122. Scott, M., Groth, D., Foster, D., et al. (1993) Propagation of prions with artificial properties in transgenic mice expressing chimeric PrP genes. Cell 73, 979-988.

123. Scott, M. R., Kohler, R., Foster, D., and Prusiner, S. B. (1992) Chimeric prion protein expression in cultured cells and transgenic mice. Protein Sci. 1, 986-997.

124. Serio, T. R., Cashikar, A. G., Kowal, A. S., et al. (2000) Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science 289, 1317-1321.

125. Shaked, G. M., Shaked, Y., Kariv, Z., Halimi, M., Avraham, I., and Gabizon, R. (2001) A protease resistant PrP isoform is present in urine of animals and humans affected with prion diseases. J. Biol. Chem. 276, 31,479-31,482.

126. Snow, A. D., Kisilevsky, R., Willmer, J., Prusiner, S. B., and DeArmond, S. J. (1989) Sulfated glycosaminoglycans in amyloid plaques of prion diseases. Acta Neuropathol. 77, 337-342.

127. Supattapone, S., Bosque, P., Muramoto, T., et al. (1999) Prion protein of 106 residues creates an artifical transmission barrier for prion replication in transgenic mice. Cell 96, 869-878.

128. Taraboulos, A., Raeber, A. J., Borchelt, D. R., Serban, D., and Prusiner, S. B. (1992) Synthesis and trafficking of prion proteins in cultured cells. Mol. Biol. Cell. 3, 851-863.

129. Taraboulos, A., Scott, M., Semenov, A., Avraham, D., Laszlo, L., and Prusiner, S. B. (1995) Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform. J. Cell. Biol. 129, 121-132.

130. Taylor, K. L., Cheng, N., Williams, R. W., Steven, A. C., and Wickner, R. B. (1999) Prion domain initiation of amyloid formation in vitro from native Ure2p. Science 283, 1339-1343.

131. Telling, G. C., Parchi, P., DeArmond, S. J., et al. (1996) Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science 274, 2079-2082.

132. Telling, G. C., Scott, M., Mastrianni, J., et al. (1995) Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell 83, 79-90.

133. Tobler, I., Gaus, S. E., Deboer, T., et al. (1996) Altered circadian activity rhythms and sleep in mice devoid of prion protein. Nature 380, 639-642.

134. Vilette, D., Andreoletti, O., Archer, F., et al. (2001) Ex vivo propagation of infectious sheep scrapie agent in heterologous epithelial cells expressing ovine prion protein. Proc. Natl. Acad. Sci. USA 98, 4055-4059.

135. Vorberg, I., Chan, K., and Priola, S. A. (2001) Deletion of beta-strand and alpha-helix secondary structure in normal prion protein inhibits formation of its protease-resistant isoform. J. Virol. 75, 10024-10032.

136. Vorberg, I., Groschup, M. H., Pfaff, E., and Priola, S. A. (2003) Multiple amino acid residues within the rabbit prion protein inhibit formation of its abnormal isoform. J. Virol. 77, 2003-2009.

137. Vorberg, I. and Priola, S. A. (2002) Molecular basis of scrapie strain glycoform variation. J. Biol. Chem. 277, 36,775-36,781.

138. Wells, G. A. H., Scott, A. C., Johnson, C. T., et al. (1987) A novel progressive spongiform encephalopathy in cattle. Vet. Rec. 121, 419-420.

139. Wickner, R. B. (1994) [URE3] as an altered URE2 protein: evidence for a prion analog in Saccharomyces cerevisiae. Science 264, 566-569.

140. Will, R. G., Ironside, J. W., Zeidler, M., et al. (1996) A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347, 921-925.

141. Williams, E. S. and Young, S. (1980) Chronic wasting disease of captive mule deer: a spongiform encephalopathy. J. Wildl. Dis. 16, 89-98.

142. Williams, E. S. and Young, S. (1982) Spongiform encephalopathy of Rocky Mountain elk. J. Wildl. Dis. 18, 465-471.

143. Zahn, R., Liu, A., Luhrs, T., et al. (2000) NMR solution structure of human prion protein. Proc. Natl. Acad. Sci. USA 97, 145-150.

144. Zulianello, L., Kaneko, K., Scott, M., et al. (2000) Dominant-negative inhibition of prion formation diminished by deletion mutagenesis of the prion protein. J. Virol. 74, 4351-4360.

Was this article helpful?

0 0
Unraveling Alzheimers Disease

Unraveling Alzheimers Disease

I leave absolutely nothing out! Everything that I learned about Alzheimer’s I share with you. This is the most comprehensive report on Alzheimer’s you will ever read. No stone is left unturned in this comprehensive report.

Get My Free Ebook

Post a comment